Skip to main content
Sign In
 

Charles A. Dinarello, MD

Professor of Medicine


 

 

Phone:  303-724-4922
Email:   charles.dinarello@ucdenver.edu
Address: Division of Infectious Diseases
12700 E. 19th Avenue Box B168
Aurora, CO  80045

 

Charles A. Dinarello is Professor of Medicine and Immunology at the University of Colorado School of Medicine in Aurora, Colorado.  Until 1996, he was Professor of Medicine at Tufts University School of Medicine and a staff physician at the New England Medical Center Hospital in Boston.  Dr. Dinarello received his medical degree from Yale University and clinical training at the Massachusetts General Hospital.  From 1971‑74, he was a clinical associate and from 1975-77, a senior investigator at the National Institutes of Health (NIH) in Bethesda.  Dr. Dinarello serves on the editorial board of several scientific journals and has published over 600 original research articles and 250 reviews and book chapters on cytokines, particularly on Interleukin-1, Tumor Necrosis Factor and related cytokines.  He has trained over 40 investigators, many of whom are now recognized experts in their fields.  The Institute for Scientific Information listed Dr. Dinarello as the world's 4th most-cited scientist during the 20 years 1983-2002.

In 1998, Dr. Dinarello was elected to the United States National Academy of Sciences and is presently serving on the editorial board of the Proceedings of the National Academy of Sciences.  He has served on the AIDS Program Advisory Council of the NIH, the Scientific Board of Advisors of the National Institute of Allergy and Infectious Diseases (NIH) and the Board of Scientific Advisors of the Alliance for Lupus Research.  He presently serves on the Board of Governors of the Weizmann Institute (Israel) and Ben Gurion University (Israel).  He is the past-Vice President of the American Society of Clinical Investigation and was President of the International Cytokine Society (1995-1996). Dr. Dinarello holds honorary degrees from the University of Marseille (France), the Weizmann Institute of Science (Israel) and the University of Frankfurt (Germany).  For his contributions to the field of cytokines, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), the Gold Medal of the Heilmeyer Society for Internal Medicine, the International Chirone Prize from the Italian National Academy of Medicine, the Carol Nachman Prize in Rheumatology, Sheikh Hamdan bin Rashdid al Maktoum Award (United Arab Emirates), the Beering Award (USA), the Albany Prize in Medicine (USA) and the Crafoord Prize from the Royal Swedish Academy of Sciences.  In March 2010, he received the Paul Ehrlich Prize (Germany) and the Bonfils Stanton Prize (Denver).   In August 2010, Dr. Dinarello will received the Novartis Prize in Immunology.

 

 

1) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity.
Journal: Proc Natl Acad Sci U S A; 99(21), Oct 15/2002, 13723-8

2) A surface amebic cysteine proteinase inactivates interleukin-18.
Journal: Infect Immun; 71(3), Mar/2003, 1274-80

3) Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha.
Journal: Am J Physiol Lung Cell Mol Physiol; 290(2), Feb/2006, L307-16

4) Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone.
Journal: Am J Respir Cell Mol Biol; 30(6), Jun/2004, 830-6

5) Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide.
Journal: Biochem J; 381(Pt 2), Jul 15/2004, 503-10

6) Peripheral blood neutrophil activation patterns are associated with pulmonary inflammatory responses to lipopolysaccharide in humans.
Journal: J Immunol; 176(12), Jun 15/2006, 7753-60

7) Differences in signaling pathways by IL-1beta and IL-18.
Journal: Proc Natl Acad Sci U S A; 101(23), Jun 8/2004, 8815-20

8) Proteinase 3 is an IL-32 binding protein.
Journal: Proc Natl Acad Sci U S A; 103(9), Feb 28/2006, 3316-21

9) Interleukin-32: a cytokine and inducer of TNFalpha.
Journal: Immunity; 22(1), Jan/2005, 131-42

10) IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
Journal: Cancer Lett; 229(2), Nov 18/2005, 261-70

11) IL-32, a proinflammatory cytokine in rheumatoid arthritis.
Journal: Proc Natl Acad Sci U S A; 103(9), Feb 28/2006, 3298-303

12) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.
Journal: Proc Natl Acad Sci U S A; 102(45), Nov 8/2005, 16309-14